ライフサイエンスコーパス: NMT

1 NMT function is essential for viability in all cell type

2 NMT inhibition, LC-MS of cell lysates, and click chemist

3 We identified 16 NMT substrates for which myristoylation was significantl

4 ters, 16.4%-19.0% (SA-SSTI) and 11.0%-19.2% (NMT-SSTI) of index cases had 1 recurrence(s).

5 Furthermore, we identified a NMT/SIRT2-ARF6 regulatory axis, which may offer new ways

6 e and die, targeting B-cell lymphomas with a NMT inhibitor potentially provides an additional much ne

7 ases in vindoline pathway promoter activity (NMT, D4H).

8 ad an IC50 > 1000 microM against C. albicans NMT did not exhibit antifungal activity and produced no

9 e nonpeptidic inhibitors of Candida albicans NMT has been synthesized starting from the octapeptide A

10 and selective inhibitors of Candida albicans NMT.

11 identity (76-77%), indicating that NMT-1 and NMT-2 comprise two distinct families of N-myristoyltrans

12 Comparisons between the NMT-1 and NMT-2 proteins revealed reduced levels of sequence ident

13 Two NMT isoforms (NMT-1 and NMT-2) are expressed in mammalian cells.

14 urrences were collected for both SA-SSTI and NMT-SSTI events.

15 on sequence play roles in replication beyond NMT recognition and Gag-membrane binding.

16 that are more widely-conserved among all BIA NMTs.

17 Functional studies showed that blocking NMT activity or modifying the N-terminus suppressed cyto

18 n excellent tool for validation of T. brucei NMT as a drug target for HAT as well as a valuable lead

19 We have previously validated T. brucei NMT as a promising druggable target for the treatment of

20 ent, brain penetrant inhibitors of T. brucei NMT.

21 myristoylation was significantly reduced by NMT inhibitor (NMTi) treatment, and, of these, 6 protein

22 Comparative analyses of caffeine NMTs demonstrate that these genes expanded through seque

23 ounds 16, 17, and 18 are competitive Candida NMT inhibitors that bind to the peptide recognition site

24 nd 61a are competitive inhibitors of Candida NMT with respect to the octapeptide substrate GNAASARR-N

25 in the discovery of the most potent Candida NMT inhibitor 61a reported to date with an IC50 of 20 nM

26 Inc., Murray Hill, New Jersey), CardioSEAL (NMT Medical Inc., Boston, Massachusetts), and STARFlex (

27 matched group of 33 non-maltreated children (NMT group) aged 10-16, completed an effort-based decisio

28 o GfTNMT appears to be similar to coclaurine NMT, with the isoquinoline rings buried deepest in the b

29 COVID-19/Flu A&B Panel in freshly collected NMT swab specimens from individuals suspected of respira

30 Recognition of different NMT isoforms by these viral and cellular substrate prote

31 s indicated the presence of several distinct NMTs in vivo, often varying in either apparent molecular

32 These studies validate L. donovani NMT as a potential target for development of new therape

33 The open reading frame of L. donovani NMT has been amplified and used to overproduce active re

34 in novel, highly potent Leishmania donovani NMT inhibitors with good selectivity over the human enzy

35 The mouse and human versions of each NMT are highly homologous, displaying greater than 95% a

36 specific inhibition or regulation of either NMT in vivo may in turn allow for the selective control

37 s with DKV, were randomly assigned to either NMT + a-tDCS (N = 17) or NMT + sham tDCS (N = 17).

38 Escherichia coli, having no endogenous NMT, is used for the coexpression of both the transferas

39 f MA by host N-myristoyltransferase enzymes (NMTs), which recognize a six-residue "myristoylation sig

40 proteins via N-myristoyltransferase enzymes (NMTs).

41 wever, specific details concerning VIP-ergic NMT are limited, largely because of difficulties in sele

42 sed N-myristoyltransferase (NMT) expression, NMTs were proposed as anti-cancer targets.

43 ts underline the importance of P. falciparum NMT as a drug target because of the pleiotropic effect o

44 ax and Plasmodium falciparum (P. falciparum) NMTs.

45 onstrated that the approximately 60-kDa FLAG-NMT binds ribosomes with higher affinity than the approx

46 nsert identified a approximately 50-kDa FLAG-NMT predominantly in the cytosolic fraction.

47 affinity than the approximately 50-kDa FLAG-NMT.

48 d containing the larger insert revealed FLAG-NMT primarily in the ribosomal fraction with an apparent

49 erial dilutions of purified recombinant FLAG-NMTs demonstrated that the approximately 60-kDa FLAG-NMT

50 en optimization of compound 1 from a focused NMT inhibitor library led to the identification of two e

51 e recognition and catalysis is not known for NMTs involved in BIA metabolism.

52 zed 15 patients who were diagnosed as having NMT or MoS as a comparative group.

53 1%) from the cohort were diagnosed as having NMT.

54 How NMTs interact with ribosomes and gain timely and specifi

55 pecifically immunoblotted with an anti-human NMT (hNMT) peptide antibody.

56 tion of a second, genetically distinct human NMT (hNMT-2), as well as the isolation of the respective

57 C1 contained nmt487D plus 10 copies of human NMT.

58 potency and excellent selectivity over human NMT.

59 While a single human NMT cDNA has been isolated and characterized (hNMT-1), b

60 ivity of 560- and 2200-fold versus the human NMT.

61 56 nM and 250-fold selectivity versus human NMT.

62 ilarities between Plasmodium vivax and human NMTs, our recent research demonstrated that high selecti

63 the inhibition of Plasmodium NMTs over human NMTs, including multiple novel scaffolds.

64 iled due to their low selectivity over human NMTs.

65 ty (>660-fold) for Leishmania NMT over human NMTs.

66 Our data demonstrate that hybridized NMT inhibitors can be multistage antimalarials, targetin

67 -purinergic, non-nitrergic (NNNP) inhibitory NMT and the role of VIP in this response.

68 ntified an ultraslow component of inhibitory NMT in the IAS mediated by VIP.

69 Two NMT isoforms (NMT-1 and NMT-2) are expressed in mammalian cells.

70 a high-throughput screen against Leishmania NMT, across 68 compounds in enzyme- and cell-based assay

71 llent selectivity (>660-fold) for Leishmania NMT over human NMTs.

72 derivatives in complex with Leishmania major NMT revealed key factors important for future structure-

73 Crystal structures bound to Leishmania major NMT were obtained, and the active diastereoisomer of one

74 n Escherichia coli by co-expressed mammalian NMT was reduced by ~70% compared to the wild-type protei

75 t functionally distinct N-methyltransferase (NMT) from opium poppy (Papaver somniferum) that primaril

76 The N-methyltransferases (NMTs) in BIA biosynthesis can be divided into three grou

77 expansions, among them N-methyltransferases (NMTs) involved in caffeine production, defense-related g

78 ionine (SAM)-dependent N-methyltransferases (NMTs) play critical roles in BIA biosynthesis, but the m

79 eomic methods and show that a small-molecule NMT inhibitor developed against related Plasmodium spp.

80 Moreover, NMT inhibitors effectively cure T. brucei infection in r

81 ell as the isolation of the respective mouse NMT homologue for each human enzyme.

82 ids possess a single N-myristoyltransferase (NMT) and multiple palmitoyl acyltransferases, and these

83 N-myristoyltransferase (NMT) attaches the fatty acid myristate to the N-terminal

84 romising drug target N-myristoyltransferase (NMT) catalyses an essential protein modification thought

85 N-Myristoyltransferase (NMT) catalyses the attachment of the 14-carbon saturated

86 N-Myristoyltransferase (NMT) catalyzes the cotranslational acylation with myrist

87 MyristoylCoA:protein N-myristoyltransferase (NMT) covalently attaches the 14-carbon saturated fatty a

88 often have increased N-myristoyltransferase (NMT) expression, NMTs were proposed as anti-cancer targe

89 t and specific human N-myristoyltransferase (NMT) inhibition.

90 N-myristoyltransferase (NMT) is a promising antimalarial drug target.

91 N-Myristoyltransferase (NMT) is a prospective drug target against parasitic prot

92 N-Myristoyltransferase (NMT) is an attractive antiprotozoan drug target.

93 N-myristoyltransferase (NMT) is an essential eukaryotic enzyme and a validated d

94 N-Myristoyltransferase (NMT) is an essential eukaryotic enzyme and an attractive

95 The enzyme N-myristoyltransferase (NMT) is an essential protein, which catalyzes the myrist

96 N-Myristoyltransferase (NMT) represents a promising drug target for human Africa

97 N-Myristoyltransferase (NMT) represents a promising drug target within the paras

98 N-Myristoyltransferase (NMT) transfers myristate to an amino-terminal glycine of

99 bitors of Leishmania N-myristoyltransferase (NMT), a potential target for the treatment of leishmania

100 gn of inhibitors for N-myristoyltransferase (NMT), an enzyme responsible for protein trafficking in P

101 N-Myristoyltransferase (NMT), an enzyme ubiquitous and essential in all eukaryot

102 zyme A (CoA):protein N-myristoyltransferase (NMT), an enzyme ubiquitous in eukaryotes that is up-regu

103 tion is catalysed by N-myristoyltransferase (NMT), an essential and druggable target in Trypanosoma c

104 an enzyme activity, N-myristoyltransferase (NMT), which transfers myristic acid from myristoyl coenz

105 yristoyl-CoA:protein N-myristoyltransferase (NMT).

106 yristoylCoA: protein N-myristoyltransferase (NMT; EC 2.1.3.97).

107 an N-terminal glycine myristoyltransferases (NMT) 1 and 2 can efficiently myristoylate specific lysin

108 N-myristoyltransferases (NMT) catalyze co- or posttranslational myristoylation of

109 N-myristoyltransferases (NMTs) cotranslationally transfer the fatty acid myristic

110 rotein synthesis by N-myristoyltransferases (NMTs), and its dysregulation has been implicated both in

111 ion is catalyzed by N-myristoyltransferases (NMTs), which transfer myristate from myristoyl coenzyme

112 Silencing N-myrystoyltransferase(NMT)-1 and casein-kinase-(CK)-II-alpha prevented Tat.AG-

113 The Nef-NMT-1 complex is most likely a transient intermediate of

114 e copy of a conditional lethal C. neoformans NMT allele was introduced into the fungal genome by homo

115 ned a single copy of wild type C. neoformans NMT.

116 ological syndromes, including neuromyotonia (NMT), Morvan syndrome (MoS), and limbic encephalitis.

117 ; 100 mum) to block purinergic and nitrergic NMT to characterize non-purinergic, non-nitrergic (NNNP)

118 s) were mediated by purinergic and nitrergic NMT.

119 The NNNP NMT was abolished by VIP6-28 (30 mum), absent in the VIP

120 tanding substrate specificity among numerous NMTs involved in the biosynthesis of BIAs and other spec

121 on 2 devices (STARFlex [umbrella occluder] [NMT Medical, Inc., Boston, Massachusetts] and Amplatzer

122 in trypanosomatids, and genetic ablation of NMT compromises virulence.

123 on ratios >1.8, indicating an association of NMT with putative ribosomal particle(s)/subunit(s).

124 of 73a and 73b is due to the attenuation of NMT activity and that NMT represents an attractive tar

125 itory profile exhibited by this new class of NMT ligands is a function of the pKa of the imidazole su

126 sound basis for the rational engineering of NMT enzymes for chemoenzymatic synthesis and metabolic e

127 and HIV-1-CRF02_AG induced the expression of NMT-1 and CKII-alpha in human monocytes and macrophages,

128 omplex with the redox-active anionic form of NMT.

129 lated by this previously unknown function of NMT.

130 at least 3 mechanisms by which inhibition of NMT can disrupt parasite development and growth: early i

131 tools for the pharmacological inhibition of NMT in living cells.

132 resulted in the expression of high levels of NMT enzyme activity.

133 vity of NMTs and cross-species reactivity of NMTs without resorting to the use of radioactive isotope

134 f interest, proof of activity/selectivity of NMTs and cross-species reactivity of NMTs without resort

135 In detailed studies of one NMT substrate, glideosome-associated protein 45 (GAP45),

136 assigned to either NMT + a-tDCS (N = 17) or NMT + sham tDCS (N = 17).

137 e distribution of transcripts encoding other NMTs, which occur predominantly in aerial plant organs.

138 ncluding B-cell lymphomas, to the potent pan-NMT inhibitor PCLX-001.

139 Pavine NMT converted racemic THP to laudanosine, but the enzyme

140 this issue, the crystal structure of pavine NMT from Thalictrum flavum was solved using selenomethio

141 his binding mode differs from that of pavine NMT, in which the benzyl ring is bound more deeply than

142 ection of selective inhibitors of Plasmodium NMT and serve as a starting point for subsequent medicin

143 es specific for the inhibition of Plasmodium NMTs over human NMTs, including multiple novel scaffolds

144 um falciparum (Pf) and Plasmodium vivax (Pv) NMT.

145 mNMT sequence was used to identify a related NMT from the common toad, Bufo bufo.

146 ing chemical moieties of previously reported NMT inhibitors to develop the next generation of PvNMT i

147 Inc., Boston, Massachusetts), and STARFlex (NMT Medical Inc.) closure devices for simple ASDs was pe

148 Through these studies, NMT-1 was identified as an abundant Nef-associated prote

149 irst inhibitor in this series with on-target NMT activity in leishmania parasites.

150 be SA-SSTI or not microbiologically tested (NMT-SSTI), were recorded within 1 calendar year and foll

151 complexes from the tetrahydroprotoberberine NMT (TNMT) subclass, specifically for GfTNMT from the ye

152 to the attenuation of NMT activity and that NMT represents an attractive tar

153 Genetic experiments have established that NMT is needed to maintain the viability of Candida albic

154 l lysine side chain, providing evidence that NMT acts both as N-terminal-lysine and glycine myristoyl

155 Here, we provide genetic evidence that NMT is likely to be essential for viability in insect st

156 sequence identity (76-77%), indicating that NMT-1 and NMT-2 comprise two distinct families of N-myri

157 Genetic studies have shown that NMT is essential for the viability of the principal fung

158 istoyl group, and our evidence suggests that NMT prefers the GTP-bound while SIRT2 prefers the GDP-bo

159 The NMT was similar across preparations, which suggested tha

160 Comparisons between the NMT-1 and NMT-2 proteins revealed reduced levels of sequ

161 Under these conditions, the NMT was predictive of contraction duty cycle but was una

162 We examined the NMT in the cardiac system of the lobster Homarus america

163 s of potent peptidomimetic inhibitors of the NMT from one such fungal pathogen, Candida albicans.

164 trategies in the presence and absence of the NMT inhibitor DDD85646, we identified 56 proteins enrich

165 Second, we assessed the ability of the NMT to predict changes in motor output induced by the ne

166 ch preparation and the nonlinear form of the NMT.

167 and found that Gag bound preferentially the NMT-2 isoform, while Hck bound mostly to NMT-1.

168 egion-of-interest, in the MT relative to the NMT group.

169 the NMT-2 isoform, while Hck bound mostly to NMT-1.

170 Unexpectedly, the sensitivity to NMT inhibitors correlates with cell's dependency on the

171 This assay should be broadly applicable to NMTs from a range of organisms.

172 detected in Nmt1-/- ES cells, but the total NMT activity levels were reduced by approximately 95%, s

173 dal-tDCS (a-tDCS) to neuromuscular training (NMT) on the dynamic knee valgus (DKV) and feedforward ac

174 ross eukaryotes and N-myristoyl transferase (NMT) has been proposed as an attractive drug target in s

175 02, an inhibitor of N-myristoyl transferase (NMT), led to a significant blockade in parasite egress f

176 viors is called the neuromuscular transform (NMT).

177 es in inhibitory neuromuscular transmission (NMT) in the internal anal sphincter (IAS).

178 nza A and B antigens in nasal mid-turbinate (NMT) swab specimens from symptomatic individuals meeting

179 Two NMT isoforms (NMT-1 and NMT-2) are expressed in mammalia

180 racterization of a third functionally unique NMT involved in benzylisoquinoline alkaloid metabolism w

181 the loosening of a flap, which in unliganded NMT structures, occludes the protein substrate binding s

182 These data further validate NMT as an exciting drug target in malaria and support 34

183 Most of the in vitro NMT activity (60-85%) in isoosmotic cell homogenates of

184 r of both Plasmodium falciparum and P. vivax NMT and displays activity in vivo against a rodent malar

185 Cocrystallization of P. vivax NMT with one compound revealed peptide binding pocket bi

186 ul discovery of a series of Plasmodium vivax NMT inhibitors by high-throughput screening.

187 activity against Plasmodium vivax (P. vivax) NMT.

188 second group, 9 of 15 patients (60.0%) with NMT or MoS were male and had a median (range) age of 51

189 tructure of the hit compound in complex with NMT was obtained, allowing understanding of its novel bi

190 Conversely, patients with NMT and MoS have anti-CASPR2 antibodies only in the seru

191 erum but not in the CSF of all patients with NMT or MoS.